COMMUNIQUÉS West-GlobeNewswire

LENSAR® to Report First Quarter 2026 Results on May 8, 2026
30/04/2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
30/04/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important [...]
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
30/04/2026
PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
30/04/2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the [...]
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
30/04/2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a company developing advanced artificial intelligence solutions for [...]
Verano Announces $20 Million Share Repurchase Authorization
30/04/2026
CHICAGO, April 30, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that its Board of Directors has [...]
UREVO Wins iF Design Award 2026 for AI-Powered Wireless Recovery Boots
30/04/2026
BERLIN, April 30, 2026 (GLOBE NEWSWIRE) -- Smart wellness innovator UREVO has been named an iF Design Award 2026 Winner for its AI-Powered Wireless Recovery Boots , reinforcing the brand's leadership in smart recovery [...]
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
30/04/2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone [...]
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
30/04/2026
Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical [...]
Northwestern Medicine Opens $15 Million Center Expanding Advanced Gastrointestinal Care to Suburban Chicago
30/04/2026
The Center for Advanced Endoscopy offers some of the most advanced endoscopic procedures available in the United States WINFIELD, Ill., April 30, 2026 (GLOBE NEWSWIRE) -- Northwestern Medicine is expanding access to [...]
EUROAPI_Contrat de liquidité
30/04/2026
Communiqué de presse Paris, 30 avril 2026 Programme de rachat d’actions Réduction de moyen au contrat de liquidité avec Kepler Cheuvreux Par contrat en date du 30 mai 2022, la société EUROAPI (ISIN: FR0014008VX5) a [...]
EUROAPI_Liquidity Contract
30/04/2026
Press Release Paris 30 avril, 2026 Share buyback program Reduction in the Resources Allocated under the Liquidity Contract with Kepler Cheuvreux By agreement dated 30 May 2022, EUROAPI (ISIN: FR0014008VX5) entrusted [...]
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
30/04/2026
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
Valneva Announces the Successful Completion of an €84 million Reserved Offering
30/04/2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine [...]
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
30/04/2026
OSE a abordé 2026 avec un plan stratégique clair à 3 ans, axé sur plusieurs catalyseurs à court terme pour lusvertikimab et Tedopi® 1 Trésorerie de 22,7 millions d’euros au 31 décembre 2025 et 17,0 millions d’euros au [...]
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
30/04/2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
30/04/2026
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi® 1 €22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, [...]
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
30/04/2026
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered [...]

Pages